Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realized

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 371, Issue 1709, 2016, Pages

  Denning, David W ^a,b  

^a Global Action Fund for Fungal Infections   (Switzerland)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Aspergillus; Cryptococcus; Histoplasma; Pneumocystis

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BACTERIUM; DISEASE INCIDENCE; DRUG; FUNGAL DISEASE; FUNGUS; INFECTIOUS DISEASE; MORTALITY; NONGOVERNMENTAL ORGANIZATION; PNEUMONIA; PUBLIC HEALTH; TUBERCULOSIS;

AJELLOMYCES; ASPERGILLUS; PNEUMOCYSTIS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMPLICATION; HUMAN; MORTALITY; MYCOSIS; THEORETICAL MODEL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; HUMANS; MODELS, THEORETICAL; MYCOSES;

EID: 84992448633     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2015.0468     Document Type: Article

References (95)

1. World Health Organization. 2014 Global Update on the Health Sector Response to HIV. See http://www.who.int/hiv/pub/progressreports/update2014/en/(accessed December 2015).
2. Jefferis K, Kinghorn A, Siphambe H, Thurlow J. 2008 Macroeconomic and household-level impacts of HIV/AIDS in Botswana. AIDS 22, S113–S119. (doi:10.1097/01.aids.0000327631.08093.66)
3. Thurlow J, Gow J, George G. 2009 HIV/AIDS, growth and poverty in KwaZulu-Natal and South Africa: an integrated survey, demographic and economy-wide analysis. J. Int. AIDS Soc. 12, 18. (doi:10.1186/1758-2652-12-18)
4. Maijama’a D, Mohammed BK. 2013 Impact of HIV/AIDS on economic growth and development in Nigeria. Int. J. Basic Appl. Sci. 1, 763–772. (doi:10.2139/ssrn.2695373)
5. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2010 Getting to zero. 2011–2015 Strategy. See http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/unaidspublication/2010/20101221_JC2034E_UNAIDS-Strategy_en.pdf (accessed December 2015).
6. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2015 Global statistics. See http://www. unaids.org/en/resources/campaigns/2014/2014gapreport/factsheet (accessed December 2015).
7. Ford N, Boulle A, Egger M. 2016 Accounting for and responding to HIV-associated mortality. AIDS 30, 521–523.
8. World Health Organization. 2014 Global tuberculosis report. See http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf (accessed December 2015).
9. Lozano R et al. 2012 Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095–2128. (doi:10.1016/S0140-6736(12)61728-0)
10. Oladele R, Denning DW. 2014 Burden of serious fungal infection in Nigeria. West Afr. J. Med. 33, 107–114.
11. Boender TS, Sigaloff KC, McMahon JH, Kiertiburanakul S, Jordan MR, Barcarolo J, Ford N, Rinke de Wit TF, Bertagnolio S. 2015 Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low-and middle-income countries: a systematic review and meta-analysis. Clin. Infect. Dis. 61, 1453–1461. (doi:10.1093/cid/civ556)
12. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. 2009 Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23, 525–530. (doi:10.1097/QAD.0b013e328322ffac)
13. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2015 AIDS by the numbers. See http://www.unaids.org/en/resources/documents/2015/AIDS_by_the_numbers_2015 (accessed December 2015).
14. Kilmarx PH, Limpakarnjanarat K, Kaewkungwal J, Srismith R, Saisorn S, Uthaivoravit W, Young NL, Mastro TD. 2000 Disease progression and survival with human immunodeficiency virus type 1 subtype E infection among female sex workers in Thailand. J. Infect. Dis. 181, 1598–1606. (doi:10.1086/315469)
15. Wandel S et al. 2008 Eligibility for ART in lower income countries (eART-linc) collaboration. Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex. Transm. Infect 84(Suppl 1), 31–i36. (doi:10.1136/sti.2008.029793)
16. Lodi S et al. CASCADE Collaboration in EuroCoord. 2011 Time from human immunodeficiency virus seroconversion to reaching CD4þ cell count thresholds,200,350, and,500 cells/mm3: assessment of need following changes in treatment guidelines. Clin. Infect Dis. 53, 817–825. (doi:10.1093/cid/cir494)
17. Cori A, Pickles M, van Sighem A, Gras L, Bezemer D, Reiss P, Fraser C. 2015 CD4þ cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, sex and calendar time. AIDS 29, 2435–2446. (doi:10.1097/QAD.0000000000000854)
18. Farahani M et al. 2016 Trends and determinants of survival for over 200 000 patients on antiretroviral treatment in the Botswana National Program: 2002–2013. AIDS 30, 477–485. (doi:10.1097/QAD.0000000000000921)
19. Schaars CF, Meintjes GA, Morroni C, Post FA, Maartens G. 2006 Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole. BMC Infect Dis. 6, 118. (doi:10.1186/1471-2334-6-118)
20. Jackson AT et al. 2012 A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. AIDS 26, 1363–1370. (doi:10.1097/QAD.0b013e328354b419)
21. Letang E et al. 2015 Cryptococcal antigenemia in immunocompromised human immunodeficiency virus patients in rural Tanzania: a preventable cause of early mortality. Open Forum Infect Dis. 2, pofv046. (doi:10.1093/ofid/ofv046)
22. Mfinanga S et al. 2015 Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet 385, 2173–2182. (doi:10.1016/S0140-6736(15)60164-7)
23. Longley N et al. 2015 Cryptococcal antigen screening in patients initiating ART in South Africa: a prospective cohort study. Clin. Infect Dis. 62, 581–587. (doi:10.1093/cid/civ936)
24. Rajasingham R, Meya DB, Boulware DR. 2012 Integrating cryptococcal antigen screening and preemptive treatment into routine HIV care. J. Acquir. Immune Defic. Syndr. 59, e85–e91. (doi:10.1097/QAI.0b013e31824c837e)
25. World Health Organization. 2011 Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children 2011. See http://www. who.int/hiv/pub/cryptococcal_disease2011/en/(accessed December 2015).
26. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, Harrison TS. 2004 Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363, 1764–1767. (doi:10.1016/S0140-6736(04)16301-0)
27. Bicanic T, Wood R, Meintjes G, Rebe K, Brouwer A, Loyse A, Bekker L, Jaffar S, Harrison T. 2008 Highdose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin. Infect. Dis. 47, 123–130. (doi:10.1086/588792)
28. Wajanga BM, Kalluvya S, Downs JA, Johnson WD, Fitzgerald DW, Peck RN. 2011 Universal screening of Tanzanian HIV-infected adult inpatients with the serum cryptococcal antigen to improve diagnosis and reduce mortality: an operational study. J. Int. AIDS Soc. 14, 48. (doi:10.1186/1758-2652-14-48)
29. Day JN et al. 2013 Combination antifungal therapy for cryptococcal meningitis. N. Engl. J. Med. 368, 1291–1302. (doi:10.1056/NEJMoa1110404)
30. Rajasingham R, Rolfes MA, Birkenkamp KE, Meya DB, Boulware DR. 2012 Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. PLoS Med. 9, e1001316. (doi:10.1371/journal.pmed.1001316)
31. Application to move Flucytosine (5FC) to Core List. 2013. See http://life-worldwide.org/media-centre/article/who-reinstates-amphotericin-b-andflucytosine-on-the-essential-medicines-li (accessed December 2015).
32. Parkes-Ratanshi R et al. 2011 Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. Lancet Infect. Dis. 11, 933–941. (doi:10.1016/S1473-3099(11)70245-6)
33. Lowe DM, Rangaka MX, Gordon F, James CD, Miller RF. 2013 Pneumocystis jirovecii pneumonia in tropical and low and middle income countries: a systematic review and meta-regression. PLoS ONE 8, e69969. (doi:10.1371/journal.pone.0069969)
34. Bedri A, Lulseged S. 2001 Clinical description of children with HIV/AIDS admitted at a referral hospital in Addis Ababa. Ethiop. Med. J. 39, 203–211.
35. Ratanasuwan W, Anekthananon T, Techasathit W, Rongrungruang Y, Sonjai A, Suwanagool S. 2005 Estimated economic losses of hospitalized AIDS patients at Siriraj Hospital from January 2003 to December 2003: time for aggressive voluntary counseling and HIV testing. J. Med. Assoc. Thai. 88, 335–339.
36. Soares VY, Lúcio Filho CE, Carvalho LI, Silva AM, Eulálio KD. 2008 Clinical and epidemiological analysis of patients with HIV/AIDS admitted to a reference hospital in the northeast region of Brazil. Rev. Inst. Med. Trop. Sao Paulo 50, 327–332. (doi:10.1590/S0036-46652008000600003)
37. Assefa G, Nigussie Y, Aderaye G, Worku A, Lindquist L. 2011 Chest x-ray evaluation of pneumonia-like syndromes in smear negative HIV-positive patients with atypical chest x-ray. Findings in Ethiopian setting. Ethiop. Med. J. 49, 35–42.
38. Bigby TD, Margolskee D, Curtis JL, Michael PF, Sheppard D, Hadley WK, Hopewell PC 1986 The usefulness of induced sputum in the diagnosis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. Am. Rev. Respir. Dis. 133, 515–518.
39. Pitchenik AE, Ganjei P, Torres A, Evans DA, Rubin E, Baier H. 1986 Sputum examination for the diagnosis of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Am. Rev. Respir. Dis. 133, 226–229.
40. Rafanan AL, Klevjer-Anderson P, Metersky ML. 1998 Pneumocystis carinii pneumonia diagnosed by noninduced sputum stained with a direct fluorescent antibody. Ann. Clin. Lab. Sci. 28, 99–103.
41. Procop GW, Haddad S, Quinn J, Wilson ML, Henshaw NG, Reller LB, Artymyshyn RL, Katanik MT, Weinstein MP. 2004 Detection of Pneumocystis jiroveci in respiratory specimens by four staining methods. J. Clin. Microbiol. 42, 3333–3335. (doi:10.1128/JCM.42.7.3333-3335.2004)
42. Fan LC, Lu HW, Cheng KB, Li HP, Xu JF. 2013 Evaluation of PCR in bronchoalveolar lavage fluid for diagnosis of Pneumocystis jirovecii pneumonia: a bivariate meta-analysis and systematic review. PLoS ONE 8, e73099. (doi:10.1371/journal.pone.0073099)
43. Nowaseb V, Gaeb E, Fraczek MG, Richardson MD, Denning DW. 2014 Frequency of Pneumocystis jirovecii in sputum from HIV and TB patients in Namibia. J. Infect. Dev. Ctries 8, 349–357. (doi:10.3855/jidc.3864)
44. Choe PG, Kang YM, Kim G, Park WB, Park SW, Kim HB, Oh M-d, Kim EC, Kim NJ. 2014 Diagnostic value of direct fluorescence antibody staining for detecting Pneumocystis jirovecii in expectorated sputum from patients with HIV infection. Med. Mycol. 52, 326–330. (doi:10.1093/mmy/myu002)
45. Morrow BM, Samuel CM, Zampoli M, Whitelaw A, Zar HJ. 2014 Pneumocystis pneumonia in South African children diagnosed by molecular methods. BMC Res. Notes 7, 26. (doi:10.1186/1756-0500-7-26)
46. Das CK, Mirdha BR, Singh S, Seth R, Bagga A, Lodha R, Kabra SK. 2014 Use of induced sputum to determine the prevalence of Pneumocystis jirovecii in immunocompromised children with pneumonia. J. Trop. Pediatr. 60, 216–222. (doi:10.1093/tropej/fmt112)
47. Karageorgopoulos DE, Qu JM, Korbila IP, Zhu YG, Vasileiou VA, Falagas ME. 2013 Accuracy of b-Dglucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clin. Microbiol. Infect. 19, 39–49. (doi:10.1111/j.1469-0691.2011.03760.x)
48. Shahrin L et al. 2014 Characteristics and predictors of death among hospitalized HIV-infected patients in a low HIV prevalence country: Bangladesh. PLoS ONE 9, e113095. (doi:10.1371/journal.pone.0113095)
49. Baéz-Saldaña R et al. 2015 Association between highly active antiretroviral therapy and type of infectious respiratory disease and all-cause inhospital mortality in patients with HIV/AIDS: a case series. PLoS ONE 10, e0138115. (doi:10.1371/journal.pone.0138115)
50. Saraceni V, King BS, Cavalcante SC, Golub JE, Lauria LM, Moulton LH, Chaisson RE, Durovni B. 2008 Tuberculosis as primary cause of death among AIDS cases in Rio de Janeiro, Brazil. Int. J. Tuberc. Lung Dis. 12, 769–772.
51. Tellez I, Barragán M, Franco-Paredes C, Petraro P, Nelson K, Del Rio C. 2008 Pneumocystis jiroveci pneumonia in patients with AIDS in the inner city: a persistent and deadly opportunistic infection. Am. J. Med. Sci. 335, 192–197. (doi:10.1097/MAJ.0b013e318152004b)
52. Lee SH et al. 2013 Trends of mortality and cause of death among HIV-infected patients in Korea, 1990–2011. J. Korean Med. Sci. 28, 67–73. (doi:10.3346/jkms.2013.28.1.67)
53. Djawe K, Buchacz K, Hsu L, Chen M-J, Selik RM, Rose C, Williams T, Brooks JT, Schwarcz S. 2015 Mortality risk after AIDS-defining opportunistic illness among HIV-infected persons—San Francisco, 1981–2012. J. Infect. Dis. 212, 1366–1375. (doi:10.1093/infdis/jiv235)
54. Gordin FM, Simon GL, Wofsy CB, Mills J. 1984 Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 100, 495–499. (doi:10.7326/0003-4819-100-4-495)
55. Helweg-Larsen J, Benfield T, Atzori C, Miller RF. 2009 Clinical efficacy of first-and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J. Antimicrob. Chemother. 64, 1282–1290. (doi:10.1093/jac/dkp372)
56. Armstrong-James D, Meintjes G, Brown GD. 2014 A neglected epidemic: fungal infections in HIV/AIDS. Trends Microbiol. 22, 120–127. (doi:10.1016/j.tim.2014.01.001)
57. Global Action Fund for Fungal Infections. 2015 ‘95–95 by 2025’ Improving outcomes for patients with fungal infections across the world: a roadmap for the next decade. See http://www.gaffi.org/roadmap/
58. Daher EF et al. 2007 Clinical and laboratory features of disseminated histoplasmosis in HIV patients from Brazil. Trop. Med. Int. Health 12, 1108–1115. (doi:10.1111/j.1365-3156.2007.01894.x)
59. Murillo J, Castro KG. 1994 HIV infection and AIDS in Latin America. Epidemiologic features and clinical manifestations. Infect Dis. Clin. North Am. 8, 1–11.
60. Lofgren SM et al. 2012 Histoplasmosis among hospitalized febrile patients in northern Tanzania. Trans. R. Soc. Trop. Med. Hyg. 106, 504–507. (doi:10.1016/j.trstmh.2012.05.009)
61. Edwards PQ, Billings EL. 1971 Worldwide pattern of skin sensitivity to histoplasmin. Am. J. Trop. Med. Hyg. 20, 288–319.
62. Nacher M et al. 2014 Histoplasmosis or tuberculosis in HIV-infected patients in the amazon: what should be treated first? PLoS Negl. Trop. Dis. 8, e3290. (doi:10.1371/journal.pntd.0003290)
63. Knox KS, Hage CA. 2010 Histoplasmosis. Proc. Am. Thorac. Soc. 7, 169–172. (doi:10.1513/pats.200907-069AL)
64. Adenis A et al. 2014 HIV-associated histoplasmosis early mortality and incidence trends: from neglect to priority. PLoS Negl. Trop. Dis. 8, e3100. (doi:10.1371/journal.pntd.0003100)
65. Caceres DH, Scheel CM, Tobón AM, Ahlquist Cleveland A, Restrepo A, Brandt ME, Chiller T, Gomez BL. 2014 Validation of an enzyme-linked immunosorbent assay that detects Histoplasma capsulatum antigenuria in Colombian patients with AIDS for diagnosis and follow-up during therapy. Clin. Vaccine Immunol. 21, 1364–1368. (doi:10.1128/CVI.00101-14)
66. Wheat J, Hafner R, Korzun AH, Limjoco MT, Spencer P, Larsen RA, Hecht FM, Powderly W. 1995 Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am. J. Med. 98, 336–342. (doi:10.1016/S0002-9343(99)80311-8)
67. Johnson PC et al. 2002 Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann. Intern. Med. 137, 105–109. (doi:10.7326/0003-4819-137-2-200207160-00008)
68. Baddley JW, Sankara IR, Rodriquez JM, Pappas PG, Many Jr WJ. 2008 Histoplasmosis in HIV-infected patients in a southern regional medical center: poor prognosis in the era of highly active antiretroviral therapy. Diagn. Microbiol. Infect. Dis. 62, 151–156. (doi:10.1016/j.diagmicrobio.2008.05.006)
69. Damasceno LS et al. 2014 Disseminated histoplasmosis in HIV-infected patients: determinants of relapse and mortality in a northeastern area of Brazil. Mycoses 57, 406–413. (doi:10.1111/myc.12175)
70. Brilhante RS et al. 2012 Histoplasmosis in HIVpositive patients in Ceará, Brazil: clinical-laboratory aspects and in vitro antifungal susceptibility of Histoplasma capsulatum isolates. Trans. R. Soc. Trop. Med. Hyg. 106, 484–488. (doi:10.1016/j.trstmh.2012.05.003)
71. Samayoa B, Mercado D, Argueta E et al. 2012 Disseminated histoplasmosis (DH) before and after the implementation of urine antigen detection ELISA (UADE) in an HIV clinic in Guatemala. In Interscience Conf. on Antimicrobial Agents and Chemotherapy, San Francisco, October 2012. Poster M-1694.
72. Denning DW, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S, Ullmann AJ, Dimopoulos G, Lange C. 2016 Chronic pulmonary aspergillosis— rationale and clinical guidelines for diagnosis and management. Eur. Resp. J. 47, 45–68. (doi:10.1183/13993003.00583-2015)
73. Godet C, Philippe B, Laurent F, Cadranel J. 2014 Chronic pulmonary aspergillosis: an update on diagnosis and treatment. Respiration 88, 162–174. (doi:10.1159/000362674)
74. Hargreaves NJ, Kadzakumanja O, Phiri S, Lee C-H, Tang X, Salaniponi FM, Harries AD, Squire SB. 2001 Pneumocystis carinii pneumonia in patients being registered for smear-negative pulmonary tuberculosis in Malawi. Trans. R. Soc. Trop. Med. Hyg. 95, 402–408. (doi:10.1016/S0035-9203(01)90197-X)
75. Nakiyingi L et al. 2015 Predictors and outcomes of mycobacteremia among HIV-infected smearnegative presumptive tuberculosis patients in Uganda. BMC Infect Dis. 15, 62. (doi:10.1186/s12879-015-0812-4)
76. Page ID, Worodria W, Andama A et al. 2016 Pulmonary aspergillosis may be common in AIDS with smear negative tuberculosis. In Conf. on Retroviruses and Opportunistic Infections, Boston, 22–25 February 2016. Abstr 16–1091.
77. Page ID, Richardson MD, Denning DW. 2016 Comparative diagnostic performance of six Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis. J. Infect. 72, 240e249. (doi:10.1016/j.jinf.2015.11.003)
78. Page I, Onyachi N, Opira C et al. 2015 Chronic cavitary pulmonary aspergillosis is a common complication of pulmonary tuberculosis: results of a cross-sectional survey. In 46th World Conf. on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union), Cape Town, South Africa 2–6 December 2015. Abstr PC-957–05. Int. J. Tuberc. Lung Dis. 19(Suppl 2), S331.
79. Anonymous. 1968 Aspergillus in persistent lung cavities after tuberculosis. A report from the Research Committee of the British Tuberculosis Association. Tubercle 49, 1–11. (doi:10.1016/S0041-3879(68)80002-9)
80. Hedayati MT, Azimi Y, Droudinia A, Mousavi B, Khalilian A, Hedayati N, Denning DW. 2015 Prevalence of chronic pulmonary aspergillosis in patients with tuberculosis from Iran. Eur. J. Clin. Microbiol. Infect Dis. 34, 1759–1765. (doi:10.1007/s10096-015-2409-7)
81. Nam HS, Jeon K, Um SW, Suh GY, Chung MP, Kim H, Kwon OJ, Koh W-J. 2010 Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int. J. Infect Dis. 14, e479–e482. (doi:10.1016/j.ijid.2009.07.011)
82. Wajanga BM, Webster LE, Peck RN, Downs JA, Mate K, Smart LR, Fitzgerald DW. 2014 Inpatient mortality of HIV-infected adults in sub-Saharan Africa and possible interventions: a mixed methods review. BMC Health Serv. Res. 14, 627. (doi:10.1186/s12913-014-0627-9)
83. Kneale M, Bartholomew JS, Davies E, Denning DW. 2016 Global access to antifungal therapy and its variable cost. J. Antimicrob. Chemother. (doi:10.1093/jac/dkw325)
84. Gray DM, Zar HJ. 2010 Community-acquired pneumonia in HIV-infected children: a global perspective. Curr. Opin. Pulm. Med. 16, 208–216. (doi:10.1097/mcp.0b013e3283387984)
85. Okwera A, Bwanga F, Najjingo I, Mulumba Y, Mafigiri DK, Whalen CC, Joloba ML. 2013 Aetiology of pulmonary symptoms in HIV-infected smear negative recurrent PTB suspects in Kampala, Uganda: a cross-sectional study. PLoS ONE 8, e82257. (doi:10.1371/journal.pone.0082257)
86. Limper AH et al. 2011 An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am. J. Respir. Crit. Care Med. 183, 96–128. (doi:10.1164/rccm.2008-740ST)
87. Denning DW, Pleuvry A, Cole DC. 2011 Global burden of chronic pulmonary aspergillosis as a sequel to tuberculosis. Bull. WHO 89, 864–872. (doi:10.2471/BLT.11.089441)
88. Khoo S, Denning DW. 1994 Aspergillus infection in the acquired immune deficiency syndrome. Clin. Infect. Dis. 19(suppl 1), 541–548.
89. Antinori S et al. 2009 Trends in the postmortem diagnosis of opportunistic invasive fungal infections in patients with AIDS: a retrospective study of 1,630 autopsies performed between 1984 and 2002. Am. J. Clin. Pathol. 132, 221–227. (doi:10.1309/AJCPRAAE8LZ7DTNE)
90. Antiretroviral Therapy Cohort Collaboration (ART-CC). 2009 Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin. Infect. Dis. 48, 1138–1151. (doi:10.1086/597468)
91. Prado M, Silva MB, Laurenti R, Travassos LR, Taborda CP. 2009 Mortality due to systemic mycoses as a primary cause of death or in association with AIDS in Brazil: a review from 1996 to 2006. Mem. Inst. Oswaldo Cruz 104, 513–521. (doi:10.1590/S0074-02762009000300019)
92. Singh VR, Smith DK, Lawerence J, Kelly PC, Thomas AR, Spitz B, Sarosi GA. 1996 Coccidioidomycosis in patients infected with human immunodeficiency virus: review of 91 cases at a single institution. Clin. Infect. Dis. 23, 563–568. (doi:10.1093/clinids/23.3.563)
93. Pappas PG et al. 1992 Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 116, 847–853. (doi:10.7326/0003-4819-116-10-847)
94. Zheng J, Gui X, Cao Q, Yang R, Yan Y, Deng L, Lio J. 2015 A clinical study of acquired immunodeficiency syndrome associated Penicillium marneffei infection from a non-endemic area in China. PLoS ONE 10, e0130376. (doi:10.1371/journal.pone.0130376)
95. Son VT, Khue PM, Strobel M. 2014 Penicilliosis and AIDS in Haiphong, Vietnam: evolution and predictive factors of death. Med. Mal. Infect. 44, 495–501. (doi:10.1016/j.medmal.2014.09.008)